“This is what management set-out to achieve for shareholders two years ago"
I don't believe that for a moment.
Good news for holders, though there isn't much to leverage off now that Cardiocell is gone. Some lessons learned the hard way here, Hopefully those lessons are applied to the future of TAVR. I'll have a think about dipping my toes back in the water, though the shark bites on my legs are yet to fully heal
Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular, page-20
-
- There are more pages in this discussion • 270 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
